APN Stock Overview
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for APN from our risk checks.
Aspen Pharmacare Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | R185.60 |
| 52 Week High | R200.88 |
| 52 Week Low | R133.28 |
| Beta | 0.74 |
| 1 Month Change | 2.83% |
| 3 Month Change | 13.32% |
| 1 Year Change | 28.65% |
| 3 Year Change | 46.26% |
| 5 Year Change | 30.67% |
| Change since IPO | 20,883.13% |
Recent News & Updates
Recent updates
Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation Is Looking A Bit Stretched At The Moment
Dec 01
Aspen Pharmacare Holdings (JSE:APN) Has A Pretty Healthy Balance Sheet
Mar 31With EPS Growth And More, Aspen Pharmacare Holdings (JSE:APN) Makes An Interesting Case
Jan 11These 4 Measures Indicate That Aspen Pharmacare Holdings (JSE:APN) Is Using Debt Reasonably Well
Oct 22We Ran A Stock Scan For Earnings Growth And Aspen Pharmacare Holdings (JSE:APN) Passed With Ease
Oct 06Aspen Pharmacare Holdings' (JSE:APN) Upcoming Dividend Will Be Larger Than Last Year's
Sep 21Aspen Pharmacare Holdings Limited (JSE:APN) Analysts Just Cut Their EPS Forecasts Substantially
Sep 08Aspen Pharmacare Holdings (JSE:APN) Is Increasing Its Dividend To ZAR3.26
Sep 07Here's Why We Think Aspen Pharmacare Holdings (JSE:APN) Might Deserve Your Attention Today
Jun 15Aspen Pharmacare Holdings (JSE:APN) Seems To Use Debt Quite Sensibly
Apr 02With EPS Growth And More, Aspen Pharmacare Holdings (JSE:APN) Is Interesting
Mar 16An Intrinsic Calculation For Aspen Pharmacare Holdings Limited (JSE:APN) Suggests It's 33% Undervalued
Mar 02Is Aspen Pharmacare Holdings (JSE:APN) A Risky Investment?
Dec 23Shareholders Will Probably Not Have Any Issues With Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation
Dec 02We Think Aspen Pharmacare Holdings' (JSE:APN) Robust Earnings Are Conservative
Oct 11After Leaping 42% Aspen Pharmacare Holdings Limited (JSE:APN) Shares Are Not Flying Under The Radar
Sep 30Aspen Pharmacare Holdings Limited (JSE:APN) Looks Just Right With A 42% Price Jump
Sep 30Shareholder Returns
| APN | ZA Pharmaceuticals | ZA Market | |
|---|---|---|---|
| 7D | 2.6% | 2.3% | -1.2% |
| 1Y | 28.6% | 15.0% | -4.9% |
Return vs Industry: APN exceeded the ZA Pharmaceuticals industry which returned 17.5% over the past year.
Return vs Market: APN exceeded the ZA Market which returned -4% over the past year.
Price Volatility
| APN volatility | |
|---|---|
| APN Average Weekly Movement | 3.2% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in ZA Market | 10.4% |
| 10% least volatile stocks in ZA Market | 3.0% |
Stable Share Price: APN is less volatile than 75% of ZA stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: APN's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1850 | 8,887 | Stephen Saad | https://www.aspenpharma.com |
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general anesthetics, muscle relaxants, and topical agents under the Anaesthetics brand; and a range of injectable anticoagulants with a focus on low molecular weight heparins, Xa inhibitors, and heparin derivatives under the Thrombosis brand.
Aspen Pharmacare Holdings Limited Fundamentals Summary
| APN fundamental statistics | |
|---|---|
| Market Cap | R82.58b |
| Earnings (TTM) | R5.23b |
| Revenue (TTM) | R40.71b |
15.8x
P/E Ratio2.0x
P/S RatioIs APN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APN income statement (TTM) | |
|---|---|
| Revenue | R40.71b |
| Cost of Revenue | R21.84b |
| Gross Profit | R18.87b |
| Other Expenses | R13.64b |
| Earnings | R5.23b |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 11.75 |
| Gross Margin | 46.35% |
| Net Profit Margin | 12.84% |
| Debt/Equity Ratio | 33.5% |
How did APN perform over the long term?
See historical performance and comparison